BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank97
3Y CAGR+186.1%
Year-over-Year Change
Year-over-year free cash flow growth rate
3Y CAGR
+186.1%/yr
Quarterly compound
Percentile
P97
Near historical high
vs 3Y Ago
23.4x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 592.12% |
| Q3 2025 | -3.30% |
| Q2 2025 | 248.67% |
| Q1 2025 | -369.77% |
| Q4 2024 | -171.93% |
| Q3 2024 | 637.49% |
| Q2 2024 | 97.18% |
| Q1 2024 | -469.25% |
| Q4 2023 | 54.64% |
| Q3 2023 | -8.31% |
| Q2 2023 | 59.55% |
| Q1 2023 | -95.58% |
| Q4 2022 | 25.27% |
| Q3 2022 | -16.49% |
| Q2 2022 | 64.20% |
| Q1 2022 | -132.98% |
| Q4 2021 | -41.99% |
| Q3 2021 | 9.85% |
| Q2 2021 | 57.09% |
| Q1 2021 | -36.42% |
| Q4 2020 | -16.57% |
| Q3 2020 | -23.51% |
| Q2 2020 | -32.97% |
| Q1 2020 | -122.24% |
| Q4 2019 | 62.02% |
| Q3 2019 | -12.74% |
| Q2 2019 | 9.24% |
| Q1 2019 | -12.46% |
| Q4 2018 | 31.32% |
| Q3 2018 | -149.08% |
| Q2 2018 | 28.48% |
| Q1 2018 | -85.14% |
| Q4 2017 | 15.73% |
| Q3 2017 | -30.25% |
| Q2 2017 | -13.58% |
| Q1 2017 | -1380.90% |
| Q4 2016 | 96.75% |
| Q3 2016 | -36.20% |
| Q2 2016 | 41.08% |
| Q1 2016 | -17.10% |